| 000 | 01691 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513170405.0 | ||
| 264 | 0 | _c19990413 | |
| 008 | 199904s 0 0 eng d | ||
| 022 | _a0006-8993 | ||
| 024 | 7 |
_a10.1016/s0006-8993(99)01065-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJohnson, M P | |
| 245 | 0 | 0 |
_aPhosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists. _h[electronic resource] |
| 260 |
_bBrain research _cMar 1999 |
||
| 300 |
_a539-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAmino Acids _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBrain Chemistry _xphysiology |
| 650 | 0 | 4 |
_aCerebellum _xenzymology |
| 650 | 0 | 4 |
_aCycloleucine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aExcitatory Amino Acid Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aGlycine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aHippocampus _xenzymology |
| 650 | 0 | 4 | _aHydrolysis |
| 650 | 0 | 4 | _aInjections, Intraventricular |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xpharmacology |
| 650 | 0 | 4 |
_aPhenylacetates _xpharmacology |
| 650 | 0 | 4 |
_aPhosphatidylinositols _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReceptors, Metabotropic Glutamate _xagonists |
| 650 | 0 | 4 |
_aResorcinols _xpharmacology |
| 650 | 0 | 4 | _aTritium |
| 650 | 0 | 4 |
_aType C Phospholipases _xmetabolism |
| 650 | 0 | 4 |
_aXanthenes _xpharmacology |
| 700 | 1 | _aChamberlain, M | |
| 700 | 1 | _aKelly, G M | |
| 773 | 0 |
_tBrain research _gvol. 821 _gno. 2 _gp. 539-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0006-8993(99)01065-3 _zAvailable from publisher's website |
| 999 |
_c10024977 _d10024977 |
||